X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BC2027 is a first-in-class antibody drug conjugate which targets Glypican 3 (GPC3), a proteoglycan found in the outer membrane of cancer cells. It is being evaluated for the treatment of liver cancer.
Lead Product(s): BC2027
Therapeutic Area: Oncology Product Name: BC2027
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
SC0062 is one of the most unique, oral endothelin A (ETA)-receptor selective antagonist, small molecule drug. It is being evaluated for the treatment of IgA Nephropathy.
Lead Product(s): SC0062
Therapeutic Area: Nephrology Product Name: SC0062
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
BioCity evaluating Phase I/II clinical trial studies of its BC3402 anti-TIM-3 monoclonal antibody in combination with Imfinzi (durvalumab) or the treatment of advanced hepatocellular carcinoma in China.
Lead Product(s): BC3402,Durvalumab
Therapeutic Area: Oncology Product Name: BC3402
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
The collaboration aims to evaluate BioCity's BC3402, a mAb targeting the T cell immunoglobulin and mucin domain-containing protein 3, in combination with AstraZeneca's anti-PD-L1 mAb IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma in China.
Lead Product(s): BC3402,Durvalumab
Therapeutic Area: Oncology Product Name: BC3402
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
BC3448 is a CD3-based BsAb that recruits T cells to tumors cells with high EGFR expression resulting in T cell-driven tumor cell killing and is being developed in solid tumors with high EGFR expression, including NSCLC, HNSCC, mCRC, and ESC.
Lead Product(s): BC3448
Therapeutic Area: Oncology Product Name: BC3448
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
BC3195 is a novel ADC targeting CDH3/P-cadherin, a calcium-dependent cell-cell adhesion glycoprotein highly expressed in a variety of malignancies, including lung, breast, gastric, ovarian, colorectal, and pancreatic cancers.
Lead Product(s): BC3195
Therapeutic Area: Oncology Product Name: BC3195
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2023
Details:
SC0062 is designed with high selectivity for ETA receptors antagonists, which is investigated for the treatment of chronic kidney disease with albuminuria.
Lead Product(s): SC0062
Therapeutic Area: Nephrology Product Name: SC0062
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
